Contract for innovative delivery system for COVID-19 vaccine
Croda International Plc (“Croda” or “the Group”), the speciality chemical company that uses smart science to create high performance ingredients and technologies that improve lives, today announces that it has recently entered into an agreement with Pfizer Inc. to supply novel excipients used in the manufacture of a COVID-19 vaccine candidate.
Smarter Innovation Through Quality
Did you miss our Smarter Innovation Through Quality virtual conference? Follow the link to access all the sessions and video content on demand. Learn about a variety of subjects from quality matters to regulatory insights and product innovations to formulation expertise.
Croda strengthens position in Health Care with the acquisition of Avanti Polar Lipids
Croda International Plc (‘Croda’) announces that it has agreed to acquire Avanti Polar Lipids, Inc. (‘Avanti’), a knowledge-intensive leader in lipid-based drug delivery technologies for next generation pharmaceuticals.
Our high purity pharmaceutical excipients, in-house formulation expertise, strong analytical capability and vaccine adjuvants portfolio make us the ideal solutions provider with whom to navigate drug and vaccine formulation challenges.
Discover what makes us a top choice for global pharmaceutical and vaccine formulators.